



CLIENT-FACING CONCEPT DECK

Minha Naseer, PhD

Minha Writes Medicine.

Interactive Medical Education Article Blueprint

 minhanr@gmail.com



Content Plan & SEO Metadata

Title / alternative title

Understanding Endometrial Cancer and Dostarlimab
Alt: Dostarlimab for Advanced Endometrial Cancer

SEO summary

Educational overview of endometrial cancer, dMMR/MSI-H biology, and the clinical rationale for PD-1 inhibition.

Keywords

Endometrial cancer, dostarlimab, MSI-H, dMMR, GARNET trial, immunotherapy, gynaecological cancer

Therapy Area

Gynae Oncology | Endometrial Cancer | Digital Med Ed

Client-review note: independent, unfunded concept sample; not approved for external medical or promotional use.

Thumbnail Concept

Abstract DNA-helix motif in brand navy/blue with article title overlay; visual system aligns with the icon and module style shown in this concept deck.

Review disclaimer & authorship

Prepared as a client-facing concept sample for discussion only. Final copy requires medical, editorial, and legal/regulatory review against the selected evidence base and local prescribing information. Independent, unsponsored concept based on published literature.

Core source for content development

Oaknin A, Tinker AV, Gilbert L, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent dMMR/MSI-H or MMRp/MSS endometrial cancer: interim results from GARNET. J Immunother Cancer. 2022;10:e003777. PMID: 35064011.

Proposed Opening Summary



Endometrial carcinoma is one of the most common gynaecological malignancies.

Regulatory Context

Indication statements should be verified against current local prescribing information before production.

Molecular Testing

Can identify clinically relevant molecular features, including dMMR/MSI-H status, that may inform classification and treatment decisions.



Anti-PD-1 Therapy

Dostarlimab blocks PD-1 interactions with PD-L1/PD-L2.

Many patients are diagnosed early and treated successfully with surgery; advanced or recurrent disease remains clinically challenging after platinum-based chemotherapy.



MSI-H/dMMR tumours: tumours with mismatch-repair defects or high microsatellite instability; these features support a biological rationale for immune-checkpoint inhibition.




Client-Review Article Blueprint

Article title and metadata

- Proposed article title + metadata package
Title, short title, SEO summary, keywords, disclaimer, thumbnail concept

Sections





Proposed Visual & Interaction System

Markers and visual cues for a modular interactive medical-education article.



Read more pop out



Carousel/slide-show of images



Information box



Video module placeholder



Text box for question



Pie chart



Drop down box

Color system



Navy



Orange



Green



Red



Light BG

Visualization style

Native editable charts for statistics; icon-in-circle section markers; rounded modules for grouped content; colour coding supported by text labels so colour is not the sole indicator of clinical meaning.



Scientific & Compliance Guardrails

- Concept-level copy is written to remain evidence-based and non-promotional.
- Interactive features are shown as placeholders for client review, not final production assets.



Source Fidelity

Key scientific claims are traceable to cited sources; final copy requires claim-by-claim reference checking.



Non-Promotional

Balanced, factual tone; no promotional language or unsupported superiority claims.



INN Usage


Medicines are referred to by International Nonproprietary Name (INN) unless a brand-specific brief requires otherwise.

Client-facing concept deck for review; no funding, grant, or sponsor acknowledgement is included.


Introduction



Endometrial carcinoma (EC) is one of the most common gynaecological malignancies. In 2018, EC had a reported global incidence of:




Most ECs are diagnosed at a localised stage; 5-year overall survival is lower with lymph-node invasion or metastasis.



 5-Year Overall Survival by Disease Stage Point
"Localised stage"


■ Localized Stage ■ Lymph-node invasion ■ Metastasis



 Source note: epidemiology and survival figures to be cross-checked against the selected reference set before production.



Current Treatment Landscape




Treatment Gap

Treatment selection after progression may be influenced by prior therapy, comorbidities and performance status.



Molecular Classification: Content Module

Content objective: show that endometrial carcinomas are not a single molecular entity.




MMR proteins + POLE + p53 assessment → Molecular classification



Rationale for PD-1 Inhibition

Why can dMMR/MSI-H biology create an opportunity for immunotherapy?




Video placeholder for MoA animation;
click to watch

Dostarlimab Mechanism of Action



1. Immune checkpoint engaged; T-cell inhibited


PD-L1 on the tumour cell binds PD-1 on the T cell, delivering an inhibitory signal that reduces T-cell activity.



Immune system (inhibited)

2. Dostarlimab blocks PD-1


Dostarlimab binds to PD-1 on T-cell, preventing PD-L1 binding and blocking the inhibitory signal.




Dostarlimab binding to PD-1

3. T-cell activity restored


PD-1 blockade can restore T-cell activation, cytokine release and cytotoxic function against tumour cells.



Restored Immune Response



Clinical Implications of Molecular Classification



 [Read the full GARNET study summary](#)

References & Source Pack

- 1 Kristeleit R et al. Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab. *Int J Gynecol Cancer*. 2022;32(10):1250-7.
- 2 Rousset-Rouviere S et al. Endometrial carcinoma: immune microenvironment and emerging treatments in immuno-oncology. *Biomedicines*. 2021;9(6):632.
- 3 Concin N et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. *Int J Gynecol Cancer*. 2021;31(1):12-39.
- 4 Cuccu I et al. Role of genomic and molecular biology in the modulation of the treatment of endometrial cancer: narrative review and perspectives. *Healthcare (Basel)*. 2023;11(4):571.
- 5 Oaknin A et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET — a phase I, single-arm study. *J Immunother Cancer*. 2022;10(1):e003777.
- 6 Yi M et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. *Mol Cancer*. 2022;21(1):28.